Swiss National Bank Purchases 9,800 Shares of Nurix Therapeutics, Inc. $NRIX

Swiss National Bank boosted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 9.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 116,700 shares of the company’s stock after purchasing an additional 9,800 shares during the quarter. Swiss National Bank owned about 0.15% of Nurix Therapeutics worth $1,386,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its holdings in Nurix Therapeutics by 1.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 582,066 shares of the company’s stock worth $6,915,000 after purchasing an additional 9,232 shares during the last quarter. Vanguard Group Inc. raised its holdings in Nurix Therapeutics by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 4,415,122 shares of the company’s stock worth $52,452,000 after purchasing an additional 69,856 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Nurix Therapeutics during the 1st quarter worth about $169,000. XTX Topco Ltd bought a new stake in Nurix Therapeutics during the 1st quarter worth about $222,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Nurix Therapeutics by 13.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,829 shares of the company’s stock worth $224,000 after purchasing an additional 2,260 shares during the last quarter.

Nurix Therapeutics Price Performance

Shares of NRIX stock opened at $9.67 on Tuesday. The stock has a market cap of $739.26 million, a PE ratio of -3.70 and a beta of 2.14. The stock has a 50-day moving average of $11.36 and a 200-day moving average of $11.95. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.27. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%.The business had revenue of $44,056 billion during the quarter, compared to analyst estimates of $16.26 million. As a group, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 4,308 shares of the business’s stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the transaction, the insider directly owned 69,023 shares in the company, valued at approximately $828,966.23. The trade was a 5.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 5,402 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the transaction, the chief financial officer owned 35,512 shares of the company’s stock, valued at $391,697.36. This represents a 13.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,014 shares of company stock valued at $163,014 over the last quarter. 7.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Morgan Stanley set a $16.00 price objective on Nurix Therapeutics and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Stephens reaffirmed an “overweight” rating and issued a $30.00 price target on shares of Nurix Therapeutics in a research note on Thursday, July 10th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price target (down from $32.00) on shares of Nurix Therapeutics in a research note on Thursday, July 31st. Finally, Wall Street Zen raised Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 21st. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $28.87.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.